I have a long-standing interest in DDR biology, research which is relevant to many human diseases including neurodegeneration, immunodeficiency, aging and cancer. Since 2005 I have led the lab’s research on ubiquitin, UBLs and the crosstalk between these modifications in response to DSBs and was appointed senior research associate in 2009. During the last years I spearheaded the integration of CRISPR-Cas9 technology into the lab for use in whole genome and focused/bespoke screens, resulting in several publications. I have formed alliances/collaborations with other labs in the UK and abroad. In addition, I have mentored, and continue to mentor, both undergraduate and graduate students. I will continue to contribute my knowledge and experience to lead and support ongoing projects in the lab, for example the search for synthetic lethality with CDKN2A deficiency in hereditary melanoma and the role of the E3 ubiquitin ligase complex CTLH in the DDR.